Table 1.
SNPs associated with BCR in patients with prostate cancer receiving RP.
| Gene SNP | Discovery | Replication | Combined | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | N | BCR | P | N | BCR | P | MST, Months | HR (95% CI) | P | HR (95% CI) a | P a |
| CD1B rs3181082 | |||||||||||
| CC | 189 | 63 | 0.053 | 74 | 30 | 0.150 | 127 | 1.00 | 1.00 | ||
| CT | 207 | 88 | 85 | 46 | 70 | 1.39 (1.07–1.81) | 0.015 | 1.41 (1.06–1.86) | 0.018 | ||
| TT | 58 | 29 | 26 | 14 | 58 | 1.42 (0.99–2.04) | 0.058 | 1.46 (1.00–2.12) | 0.050 | ||
| CT/TT vs. CC | 0.045 | 0.080 | 1.40 (1.09–1.80) | 0.009 | 1.42 (1.09–1.85) | 0.010 | |||||
| TT vs. CC/CT | 0.314 | 0.692 | 1.19 (0.86–1.64) | 0.308 | 1.21 (0.86–1.69) | 0.270 | |||||
| CD1C rs76926515 | |||||||||||
| AA | 359 | 135 | 0.155 | 151 | 69 | 0.421 | 102 | 1.00 | 1.00 | ||
| AG | 37 | 20 | 31 | 21 | 45 | 1.74 (1.25–2.44) | 0.001 | 1.47 (1.03–2.11) | 0.036 | ||
| GG | 3 | 0 | 3 | 0 | – | – | – | ||||
| AG/GG vs. AA | 0.030 | 0.136 | 1.52 (1.09–2.13) | 0.014 | 1.37 (0.95–1.96) | 0.090 | |||||
Abbreviations: SNP, single nucleotide polymorphism; BCR, biochemical recurrence; MST, median BCR-free survival time; RP, radical prostatectomy; HR, hazard ratio; CI, confidence interval. a Adjustment for age, PSA at diagnosis, pathologic Gleason score, stage, and lymph node metastasis. p < 0.05 are in boldface.